These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 15580358)

  • 1. Haemophilia A in two premature infants.
    Bidlingmaier C; Bergmann F; Kurnik K
    Eur J Pediatr; 2005 Feb; 164(2):70-2. PubMed ID: 15580358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allergic reaction in a cohort of haemophilia A patients using plasma-derived factor VIII (FVIII) concentrate is rare and not necessarily triggered by FVIII.
    Montalvão SA; Tucunduva AC; Siqueira LH; Sambo AL; Medina SS; Ozelo MC
    Haemophilia; 2015 Jul; 21(4):e281-5. PubMed ID: 25929310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII.
    Hermans C; Mahlangu J; Booth J; Schütz H; Santagostino E; Young G; Lee HY; Steinitz-Trost KN; Blanchette V; Berntorp E
    Haemophilia; 2018 May; 24(3):376-384. PubMed ID: 29732708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis--a meta-analysis.
    Gruppo RA; Brown D; Wilkes MM; Navickis RJ
    Haemophilia; 2003 May; 9(3):251-60. PubMed ID: 12694514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No immunological changes after factor VIII product switch: An in depth analysis in haemophilia A patients.
    Schep SJ; Fischer K; Boes M; Schutgens REG
    Haemophilia; 2023 Jul; 29(4):1039-1048. PubMed ID: 37276354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.
    Epstein J; Xiong Y; Woo P; Li-McLeod J; Spotts G
    Haemophilia; 2012 Mar; 18(2):187-92. PubMed ID: 21883704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
    Mannucci PM; Shi Q; Bonanad S; Klamroth R
    Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
    Meunier S; Alamelu J; Ehrenforth S; Hanabusa H; Abdul Karim F; Kavakli K; Khodaie M; Staber J; Stasyshyn O; Yee DL; Rageliene L
    Thromb Haemost; 2017 Aug; 117(9):1705-1713. PubMed ID: 28692108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group.
    Seremetis S; Lusher JM; Abildgaard CF; Kasper CK; Allred R; Hurst D
    Haemophilia; 1999 Jan; 5(1):9-16. PubMed ID: 10215942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group.
    White GC; Courter S; Bray GL; Lee M; Gomperts ED
    Thromb Haemost; 1997 Apr; 77(4):660-7. PubMed ID: 9134639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.
    Berntorp E; Negrier C; Gozzi P; Blaas PM; Lethagen S
    Haemophilia; 2016 May; 22(3):389-96. PubMed ID: 26863900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A.
    Fukui H; Yoshioka A; Shima M; Tanaka I; Koshihara K; Fukutake K; Fujimaki M
    Int J Hematol; 1991 Oct; 54(5):419-27. PubMed ID: 1756252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SHP656, a polysialylated recombinant factor VIII (PSA-rFVIII): First-in-human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A.
    Tiede A; Allen G; Bauer A; Chowdary P; Collins P; Goldstein B; Jiang HJ; Kӧck K; Takács I; Timofeeva M; Wolfsegger M; Srivastava S
    Haemophilia; 2020 Jan; 26(1):47-55. PubMed ID: 31778283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Inhibitor development against FVIII in previously treated patients with haemophilia A. A retrospective data collection].
    Siegmund B; Pollmann H; Richter H; Orlovic M; Gottstein S; Klamroth R
    Hamostaseologie; 2010 Nov; 30 Suppl 1():S37-9. PubMed ID: 21042673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of bleeding disorders: basic science.
    Ofosu FA; Santagostino E; Grancha S; Marco P
    Haemophilia; 2012 May; 18 Suppl 2():8-14. PubMed ID: 22530574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spotlight on the human factor: building a foundation for the future of haemophilia A management: report from a symposium on human recombinant FVIII at the World Federation of Hemophilia World Congress, Melbourne, Australia on 12 May 2014.
    Kessler C; Oldenburg J; Ettingshausen CE; Tiede A; Khair K; Négrier C; Klamroth R
    Haemophilia; 2015 Jan; 21 Suppl 1():1-12. PubMed ID: 25472812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant factor VIII: past, present and future of treatment of hemophilia A.
    Raso S; Hermans C
    Drugs Today (Barc); 2018 Apr; 54(4):269-281. PubMed ID: 29869648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients.
    Brand B; Gruppo R; Wynn TT; Griskevicius L; Lopez Fernandez MF; Chapman M; Dvorak T; Pavlova BG; Abbuehl BE
    Haemophilia; 2016 Jul; 22(4):e251-8. PubMed ID: 27328112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Forum on: the role of recombinant factor VIII in children with severe haemophilia A.
    Franchini M; Coppola A; Molinari AC; Santoro C; Schinco P; Speciale V; Tagliaferri A
    Haemophilia; 2009 Mar; 15(2):578-86. PubMed ID: 19187188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
    Kreuz W; Escuriola Ettingshausen C; Vdovin V; Zozulya N; Plyushch O; Svirin P; Andreeva T; Bubanská E; Campos M; Benedik-Dolničar M; Jiménez-Yuste V; Kitanovski L; Klukowska A; Momot A; Osmulskaya N; Prieto M; Šalek SZ; Velasco F; Pavlova A; Oldenburg J; Knaub S; Jansen M; Belyanskaya L; Walter O; ;
    Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.